DemetrixContactcontact@demetrix.comhttp://www.demetrix.com/Articles & NewsConsumers/Market20% CAGR Forecasted for CBG, Other Minor Cannabinoids from 2021-2028Collaborations, clinical trials and production by key players contribute to increased awareness and adoption, per Research and Markets. In relation, fermentation offers an alternative method to product CBG; an upcoming webcast from Demetrix explains.IngredientsDemetrix x Evonik Sign Supply Agreement for CannabinoidsThis partnership will introduce CBG to global beauty and personal care markets.IngredientsDemetrix Initiates 2022 CBG Commercial Manufacturing CampaignDemetrix’s commercial manufacturing campaign will support anticipated market demand and partnerships in 2022 with expanded production in 2023 and beyond.CompaniesDemetrix Signs First CMO for Cannabinoid ProductionDemetrix signed its first contract manufacturing organization for the commercial scale production of cannabinoids such as CBG for nutraceutical, skin care and other consumer health and wellness products.Webcast & EventsWebcastSkincare’s Newest Bioactive Ingredient: CBGOn-DemandMay 12th, 2022Demetrix invites you to discover the benefits and explore the possibilities of bioactive ingredients.Watch Now
